Onconetix Q3 2025 Earnings Results & Report

Onconetix EPS Results

• Actual EPS: -$3,125.00
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Onconetix Revenue Results

• Actual Revenue: $303.65 thousand
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Onconetix (NASDAQ:ONCO) is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions.

Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels. Proclarix was developed to provide additional information that may help physicians determine whether further diagnostic evaluation, such as a prostate biopsy, is appropriate.

Onconetix has also pursued pharmaceutical products for benign prostatic hyperplasia (BPH), including ENTADFI, a combination of tadalafil and finasteride intended to treat the symptoms and underlying causes of enlarged prostate. The company’s current strategy is focused on advancing and commercializing its men’s-health platform through regulatory, clinical and commercial activities in the United States and international markets where its products are authorized or available.

The company was formerly known as Blue Water Vaccines, Inc. and adopted the Onconetix name following a business combination involving Onconetix, Inc. While the company has publicly discussed its men’s-health products and corporate transactions, detailed information about its operating geographies and leadership may change over time and should be reviewed in its latest regulatory filings.